Walvax COVID-19 vaccine
Vaccine candidate against COVID-19 / From Wikipedia, the free encyclopedia
AWcorna, originally termed ARCoV[1] and also known as the Walvax COVID-19 vaccine, is an mRNA COVID-19 vaccine developed by Walvax Biotechnology, Suzhou Abogen Biosciences, and the PLA Academy of Military Science.[2] In contrast to other mRNA COVID vaccines, such as those by Pfizer-BioNtech and Moderna, this vaccine primarily targets the Sars-CoV-2 receptor-binding domain of the spike protein, rather than the entire spike protein.[3] It is approved for Phase III trials in China,[4] Mexico,[5] Indonesia,[6] and Nepal.[7]
Quick Facts Vaccine description, Target ...
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | mRNA |
Clinical data | |
Routes of administration | Intramuscular |
Identifiers | |
DrugBank |
Close
It granted emergency use approval in Indonesia in September 2022.[8]